Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.

ABSTRACT:

Background

The B₂ receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients.

Objective

We sought to test the hypothesis that a bradykinin B₂ receptor antagonist would shorten time-to-resolution from ACE inhibitor-associated angioedema.

Methods

Patients with ACE inhibitor-associated angioedema (defined as swelling of lips, tongue, pharynx, or face during ACE inhibitor use and no swelling in the absence of ACE inhibitor use) were enrolled at Vanderbilt University Medical Center from October 2007 through September 2015 and at Massachusetts General Hospital

SUBMITTER: Straka BT 

PROVIDER: S-EPMC5705179 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature